AXL and B-cell chronic lymphocytic leukemia: In preclinical studies, TP-0903 — a small molecule originally developed as an AXL inhibitor (17) — demonstrated anticancer activity in chronic lymphocytic leukemia (CLL), invasive breast cancer, and neuroblastoma (18–20).